SILO
Silo Pharma, Inc.
Biotechnology
Market Cap$2M
5Y Perf.+20.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
SILO vs PSTV vs CMPS vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
PSTV
Plus Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-99.3%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-78.6%
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-99.5%
SILO vs PSTV vs CMPS vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SILO | PSTV | CMPS | NRXP |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Care Facilities | Biotechnology |
| Market Cap | $2M | $14M | $902M | $85M |
| Revenue (TTM) | $72K | $5M | $0.00 | $242K |
| Net Income (TTM) | $-5M | $-22M | $-288M | $-38M |
| Gross Margin | -8.1% | 91.5% | — | 59.5% |
| Operating Margin | -74.5% | -293.5% | — | -63.0% |
| Total Debt | $0.00 | $821K | $21M | $631K |
| Cash & Equiv. | $4M | $9M | $150M | $8M |
SILO vs PSTV vs CMPS vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SILO
PSTV
CMPS
NRXP
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Silo Pharma, Inc. (SILO) | 100 | 120.3 | +20.3% |
| Plus Therapeutics, … (PSTV) | 100 | 0.7 | -99.3% |
| COMPASS Pathways plc (CMPS) | 100 | 21.4 | -78.6% |
| NRx Pharmaceuticals… (NRXP) | 100 | 0.5 | -99.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SILO vs PSTV vs CMPS vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Silo Pharma, Inc. is the stronger pick specifically for operational efficiency and capital deployment. NRXP also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SILO
Silo Pharma, Inc.
The Growth Play
SILO is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 0.0%, EPS growth 0.8%, 3Y rev CAGR 0.4%
- 20.0% 10Y total return vs CMPS's -67.6%
- -79.5% ROA vs NRXP's -489.9%
Best for: growth exposure and long-term compounding
PSTV
Plus Therapeutics, Inc.
The Income Pick
PSTV is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.82
Best for: income & stability
CMPS
COMPASS Pathways plc
The Defensive Pick
CMPS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 1.33, current ratio 0.77x
- Beta 1.33, current ratio 0.77x
- 1.3% margin vs NRXP's -157.3%
- Beta 1.33 vs SILO's 2.21
Best for: sleep-well-at-night and defensive
NRXP
NRx Pharmaceuticals, Inc.
The Growth Leader
NRXP is the clearest fit if your priority is growth.
- 101.1% revenue growth vs CMPS's -85.7%
Best for: growth
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs CMPS's -85.7% |
| Quality / Margins | CMPS | 1.3% margin vs NRXP's -157.3% |
| Stability / Safety | CMPS | Beta 1.33 vs SILO's 2.21 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | CMPS | +151.1% vs PSTV's -57.8% |
| Efficiency (ROA) | SILO | -79.5% ROA vs NRXP's -489.9% |
SILO vs PSTV vs CMPS vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
Segment breakdown not available.
FY 2025
SILO vs PSTV vs CMPS vs NRXP — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPSTVLAGGINGNRXP
Who Leads Where
PSTV leads in 2 of 6 categories
CMPS leads 2 • SILO leads 1 • NRXP leads 0 • 1 tied
Explore the data ↓NRXPNRx Pharmaceuticals, …
0leads
SILOSilo Pharma, Inc.
1leads
CMPSCOMPASS Pathways plc
2leads
PSTVPlus Therapeutics, In…
2leads
6 Total Categories
CATEGORYLEADERvs CMPSvs SILOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PSTV5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SILO4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CMPS4/6
Risk & VolatilityBeta, volatility, and downside exposure
CMPS2/2
Analyst OutlookRatings, price targets, and dividends
PSTV1/1
Income & Cash Flow (Last 12 Months)
PSTV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PSTV and CMPS operate at a comparable scale, with $5M and $0 in trailing revenue. PSTV is the more profitable business, keeping -4.3% of every revenue dollar as net income compared to NRXP's -157.3%. On growth, SILO holds the edge at 0.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… | CMPSCOMPASS Pathways … | NRXPNRx Pharmaceutica… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $72,102 | $5M | $0 | $242,000 |
| EBITDAEarnings before interest/tax | -$5M | -$15M | -$179M | -$31M |
| Net IncomeAfter-tax profit | -$5M | -$22M | -$288M | -$38M |
| Free Cash FlowCash after capex | -$5M | -$21M | -$157M | -$12M |
| Gross MarginGross profit ÷ Revenue | -8.1% | +91.5% | — | +59.5% |
| Operating MarginEBIT ÷ Revenue | -74.5% | -2.9% | — | -63.0% |
| Net MarginNet income ÷ Revenue | -70.4% | -4.3% | — | -157.3% |
| FCF MarginFCF ÷ Revenue | -66.6% | -4.0% | — | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | 0.0% | -3.2% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +45.5% | +100.0% | -58.7% | -80.0% |
PSTV leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — SILO and PSTV and CMPS each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… | CMPSCOMPASS Pathways … | NRXPNRx Pharmaceutica… |
|---|---|---|---|---|
| Market CapShares × price | $2M | $14M | $902M | $85M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $6M | $774M | $78M |
| Trailing P/EPrice ÷ TTM EPS | -0.35x | -0.83x | -3.05x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 26.12x | 2.76x | — | 69.15x |
| Price / BookPrice ÷ Book value/share | 0.31x | 4.63x | — | — |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — SILO and PSTV and CMPS each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
SILO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
SILO delivers a -101.4% return on equity — every $100 of shareholder capital generates $-101 in annual profit, vs $-6 for PSTV. On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs CMPS's 2/9, reflecting solid financial health.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… | CMPSCOMPASS Pathways … | NRXPNRx Pharmaceutica… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -101.4% | -5.6% | -3.4% | — |
| ROA (TTM)Return on assets | -79.5% | -156.0% | -106.8% | -4.9% |
| ROICReturn on invested capital | -186.7% | — | — | — |
| ROCEReturn on capital employed | -74.0% | -3.8% | -2.5% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 2 | 5 |
| Debt / EquityFinancial leverage | — | 0.21x | — | — |
| Net DebtTotal debt minus cash | -$4M | -$8M | -$129M | -$7M |
| Cash & Equiv.Liquid assets | $4M | $9M | $150M | $8M |
| Total DebtShort + long-term debt | $0 | $821,000 | $21M | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | -1053.72x | -4.07x | -52.40x | -24.18x |
SILO leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CMPS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SILO five years ago would be worth $16,471 today (with dividends reinvested), compared to $73 for PSTV. Over the past 12 months, CMPS leads with a +151.1% total return vs PSTV's -57.8%. The 3-year compound annual growth rate (CAGR) favors CMPS at 3.5% vs PSTV's -61.6% — a key indicator of consistent wealth creation.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… | CMPSCOMPASS Pathways … | NRXPNRx Pharmaceutica… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +25.0% | -57.1% | +43.4% | +16.8% |
| 1-Year ReturnPast 12 months | -48.1% | -57.8% | +151.1% | +55.3% |
| 3-Year ReturnCumulative with dividends | -81.1% | -94.3% | +11.0% | -50.6% |
| 5-Year ReturnCumulative with dividends | +64.7% | -99.3% | -72.4% | -99.1% |
| 10-Year ReturnCumulative with dividends | +20.0% | -100.0% | -67.6% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -42.6% | -61.6% | +3.5% | -21.0% |
CMPS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
CMPS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CMPS is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than SILO's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CMPS currently trades 92.0% from its 52-week high vs PSTV's 25.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… | CMPSCOMPASS Pathways … | NRXPNRx Pharmaceutica… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.21x | 1.82x | 1.33x | 1.91x |
| 52-Week HighHighest price in past year | $1.13 | $23.43 | $10.21 | $3.84 |
| 52-Week LowLowest price in past year | $0.22 | $0.27 | $2.25 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +37.2% | +25.4% | +92.0% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 47.0 | 49.8 | 68.1 | 64.7 |
| Avg Volume (50D)Average daily shares traded | 4.6M | 355K | 3.7M | 913K |
CMPS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
PSTV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | SILOSilo Pharma, Inc. | PSTVPlus Therapeutics… | CMPSCOMPASS Pathways … | NRXPNRx Pharmaceutica… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | — |
| Price TargetConsensus 12-month target | — | — | $17.83 | — |
| # AnalystsCovering analysts | — | — | 13 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +9.2% | 0.0% | 0.0% | 0.0% |
PSTV leads this category, winning 1 of 1 comparable metric.
Key Takeaway
PSTV leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). CMPS leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallPlus Therapeutics, Inc. (PSTV)Leads 2 of 6 categories
Loading custom metrics...
SILO vs PSTV vs CMPS vs NRXP: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is SILO or PSTV or CMPS or NRXP a better buy right now?
Analysts rate COMPASS Pathways plc (CMPS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SILO or PSTV or CMPS or NRXP?
Over the past 5 years, Silo Pharma, Inc.
(SILO) delivered a total return of +64. 7%, compared to -99. 3% for Plus Therapeutics, Inc. (PSTV). Over 10 years, the gap is even starker: SILO returned +20. 0% versus PSTV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SILO or PSTV or CMPS or NRXP?
By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.
33β versus Silo Pharma, Inc. 's 2. 21β — meaning SILO is approximately 66% more volatile than CMPS relative to the S&P 500.
04Which is growing faster — SILO or PSTV or CMPS or NRXP?
On earnings-per-share growth, the picture is similar: Plus Therapeutics, Inc.
grew EPS 100. 0% year-over-year, compared to -33. 9% for COMPASS Pathways plc. Over a 3-year CAGR, PSTV leads at 185. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SILO or PSTV or CMPS or NRXP?
COMPASS Pathways plc (CMPS) is the more profitable company, earning 0.
0% net margin versus -60. 9% for Silo Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPS leads at 0. 0% versus -65. 3% for SILO. At the gross margin level — before operating expenses — SILO leads at 91. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SILO or PSTV or CMPS or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SILO or PSTV or CMPS or NRXP better for a retirement portfolio?
For long-horizon retirement investors, COMPASS Pathways plc (CMPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Silo Pharma, Inc. (SILO) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CMPS: -67. 6%, SILO: +20. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SILO and PSTV and CMPS and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SILO: 0.0% · PSTV: -3.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.